Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SHANGHAI, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data...
-
SHENZHEN, CHINA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an...
-
BEIJING, Jan. 29, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing...
-
Soficitinib demonstrated a favorable safety profile and encouraging efficacy in treating patients with moderate-to-severe AD.
-
WeRide today launched WeRide GENESIS, its proprietary general simulation model designed to accelerate the development, training, and validation of AVs.
-
גואנגג'ואו, סין, Jan. 28, 2026 (GLOBE NEWSWIRE) -- WeRide (HKEX: 0800.HK , נאסד"ק: WRD), מובילה עולמית בטכנולוגיית נהיגה אוטונומית, הכריזה על השקת WeRide GENESIS1, מודל ההדמיה למטרות כלליות...
-
CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an...
-
Fangzhou expects full-year revenue for 2025 to reach between RMB 3.5 billion and RMB 3.55 billion, representing year-on-year growth of approximately 30%
-
Fangzhou plans to allocate approximately 90% of the net proceeds to accelerate development of the Company's AI-driven chronic disease management platform.
-
SHANGHAI, China, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Hesai Group (“Hesai” or the “Company”) (NASDAQ: HSAI; HKEX: 2525), the global leader in three-dimensional light detection and ranging (lidar)...